(Q38221687)

31 August 2017

Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development (English)

1 reference

31 August 2017

acute myeloid leukemia

1 reference

Melanie Janning

1

1 reference

PubMed ID

24947257

31 August 2017

Walter Fiedler

series ordinal

2

1 reference

PubMed ID

24947257

31 August 2017

language of work or name

English

0 references

publication date

1 May 2014

1 reference

31 August 2017

1 reference

31 August 2017

10

1 reference

31 August 2017

7

1 reference

31 August 2017

1157-1165

1 reference

Therapeutic advances in acute myeloid leukemia

31 August 2017

1 reference

Acute myeloid leukaemia in adults

21 January 2018

1 reference

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

Age and acute myeloid leukemia

21 January 2018

1 reference

AML in older patients: are we making progress?

21 January 2018

1 reference

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

21 January 2018

1 reference

Shared and separate functions of polo-like kinases and aurora kinases in cancer

21 January 2018

1 reference

Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia.

21 January 2018

1 reference

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells.

21 January 2018

1 reference

Targeting polo-like kinase 1 for cancer therapy.

21 January 2018

1 reference

Polo-like kinases and the orchestration of cell division

21 January 2018

1 reference

Polo-like kinases: a team in control of the division

21 January 2018

1 reference

Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk.

21 January 2018

1 reference

Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology

21 January 2018

1 reference

Polo-like kinase 1 as target for cancer therapy

21 January 2018

1 reference

Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers

21 January 2018

1 reference

Polo-like kinase 1 expression is a prognostic factor in human colon cancer

21 January 2018

1 reference

Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications

21 January 2018

1 reference

Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer.

21 January 2018

1 reference

Current clinical trials with polo-like kinase 1 inhibitors in solid tumors

21 January 2018

1 reference

Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies

21 January 2018

1 reference

A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.

21 January 2018

1 reference

Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies

21 January 2018

1 reference

NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.

21 January 2018

1 reference

TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens

21 January 2018

1 reference

ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress

21 January 2018

1 reference

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

21 January 2018

1 reference

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity

21 January 2018

1 reference

Structure of the catalytic domain of human polo-like kinase 1

21 January 2018

1 reference

Selectivity-determining residues in Plk1

21 January 2018

1 reference

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

21 January 2018

1 reference

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

21 January 2018

1 reference

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

21 January 2018

1 reference

An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

21 January 2018

1 reference

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.14.53

1 reference

31 August 2017

1 reference

PubMed ID

24947257